Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. Gimenez-Arnau AM, Szalewski R, Hide M, Jain V, et al. J Allergy Clin Immunol 2026;157:143-154.

Read + Share

Amedeo Smart

Independent Medical Education

Gimenez-Arnau AM, Szalewski R, Hide M, Jain V, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. J Allergy Clin Immunol 2026;157:143-154.
PMID: 41115533